Literature DB >> 17329355

Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.

Daniel De Paula1, M Vitória L B Bentley, Ram I Mahato.   

Abstract

RNA interference (RNAi) is an evolutionarily conserved process by which double-stranded small interfering RNA (siRNA) induces sequence-specific, post-transcriptional gene silencing. Unlike other mRNA targeting strategies, RNAi takes advantage of the physiological gene silencing machinery. The potential use of siRNA as therapeutic agents has attracted great attention as a novel approach for treating severe and chronic diseases. RNAi can be achieved by either delivery of chemically synthesized siRNAs or endogenous expression of small hairpin RNA, siRNA, and microRNA (miRNA). However, the relatively high dose of siRNA required for gene silencing limits its therapeutic applications. This review discusses several strategies to improve therapeutic efficacy as well as to abrogate off-target effects and immunostimulation caused by siRNAs. There is an in-depth discussion on various issues related to the (1) mechanisms of RNAi, (2) methods of siRNA production, (3) barriers to RNAi-based therapies, (4) biodistribution, (5) design of siRNA molecules, (6) chemical modification and bioconjugation, (7) complex formation with lipids and polymers, (8) encapsulation into lipid particles, and (9) target specificity for enhanced therapeutic effectiveness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329355      PMCID: PMC1831859          DOI: 10.1261/rna.459807

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  151 in total

1.  Escort aptamers: a delivery service for diagnosis and therapy.

Authors:  B J Hicke; A W Stephens
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

2.  Escherichia coli ribonuclease III: affinity purification of hexahistidine-tagged enzyme and assays for substrate binding and cleavage.

Authors:  A K Amarasinghe; I Calin-Jageman; A Harmouch; W Sun; A W Nicholson
Journal:  Methods Enzymol       Date:  2001       Impact factor: 1.600

Review 3.  Development of biomaterials for gene therapy.

Authors:  S Han; R I Mahato; Y K Sung; S W Kim
Journal:  Mol Ther       Date:  2000-10       Impact factor: 11.454

4.  Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing.

Authors:  Aimee L Jackson; Julja Burchard; Devin Leake; Angela Reynolds; Janell Schelter; Jie Guo; Jason M Johnson; Lee Lim; Jon Karpilow; Kim Nichols; William Marshall; Anastasia Khvorova; Peter S Linsley
Journal:  RNA       Date:  2006-05-08       Impact factor: 4.942

5.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.

Authors:  Dirk Grimm; Konrad L Streetz; Catherine L Jopling; Theresa A Storm; Kusum Pandey; Corrine R Davis; Patricia Marion; Felix Salazar; Mark A Kay
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

6.  Structural studies of LNA:RNA duplexes by NMR: conformations and implications for RNase H activity.

Authors:  K Bondensgaard; M Petersen; S K Singh; V K Rajwanshi; R Kumar; J Wengel; J P Jacobsen
Journal:  Chemistry       Date:  2000-08-04       Impact factor: 5.236

7.  Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter.

Authors:  J Ohkawa; K Taira
Journal:  Hum Gene Ther       Date:  2000-03-01       Impact factor: 5.695

8.  Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization.

Authors:  Mouldy Sioud
Journal:  J Mol Biol       Date:  2005-03-22       Impact factor: 5.469

9.  Aptamer mediated siRNA delivery.

Authors:  Ted C Chu; Karen Y Twu; Andrew D Ellington; Matthew Levy
Journal:  Nucleic Acids Res       Date:  2006-06-01       Impact factor: 16.971

10.  Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference.

Authors:  Thomas W Geisbert; Lisa E Hensley; Elliott Kagan; Erik Zhaoying Yu; Joan B Geisbert; Kathleen Daddario-DiCaprio; Elizabeth A Fritz; Peter B Jahrling; Kevin McClintock; Janet R Phelps; Amy C H Lee; Adam Judge; Lloyd B Jeffs; Ian MacLachlan
Journal:  J Infect Dis       Date:  2006-05-10       Impact factor: 5.226

View more
  70 in total

1.  Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs.

Authors:  Pinal C Patel; Liangliang Hao; Weng Si Au Yeung; Chad A Mirkin
Journal:  Mol Pharm       Date:  2011-06-28       Impact factor: 4.939

Review 2.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

Review 3.  Tracking miRNAs' footprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy.

Authors:  Nazila Nouraee; Seyed Javad Mowla; George A Calin
Journal:  Genes Chromosomes Cancer       Date:  2015-03-31       Impact factor: 5.006

Review 4.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

Review 5.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

6.  Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs.

Authors:  Lin Zhu; Federico Perche; Tao Wang; Vladimir P Torchilin
Journal:  Biomaterials       Date:  2014-02-13       Impact factor: 12.479

Review 7.  siRNA-based therapeutic approaches for rheumatic diseases.

Authors:  Florence Apparailly; Christian Jorgensen
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

8.  Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes.

Authors:  Hang Yuan; Linda Lanting; Zhong-Gao Xu; Shu-Lian Li; Piotr Swiderski; Sumanth Putta; Mahesh Jonnalagadda; Mitsuo Kato; Rama Natarajan
Journal:  Am J Physiol Renal Physiol       Date:  2008-06-18

Review 9.  Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids.

Authors:  Arnaud Gissot; Michel Camplo; Mark W Grinstaff; Philippe Barthélémy
Journal:  Org Biomol Chem       Date:  2008-03-05       Impact factor: 3.876

Review 10.  Lipid-based nanotherapeutics for siRNA delivery.

Authors:  A Schroeder; C G Levins; C Cortez; R Langer; D G Anderson
Journal:  J Intern Med       Date:  2010-01       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.